Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803856 | 0.92 | PTGES (0.40) | PTGESSRD5A1PTGES2SRD5A2HDAC6 | |
| SCHEMBL978497 | 0.90 | PTGES (0.43) | PTGESSRD5A1PTGES2SRD5A2HDAC6 | |
| SCHEMBL978002 | 0.87 | PTGES (0.45) | PTGESSRD5A1PTGES2SRD5A2HDAC6 | |
| SCHEMBL2802109 | 0.86 | PTGES (0.42) | PTGESSRD5A1PTGES2SRD5A2HDAC6 | |
| SCHEMBL979507 | 0.84 | PTGES (0.54) | PTGESPTGES2MAOBALDH1A1LMNA | |
| SCHEMBL2801464 | 0.84 | PTGES (0.47) | PTGESSRD5A1PTGES2SRD5A2HDAC6 | |
| SCHEMBL978846 | 0.82 | PTGES (0.49) | PTGESPTGES2HDAC6MAOBCA1 | |
| SCHEMBL981402 | 0.82 | PTGES (0.45) | PTGESPTGES2HDAC6MAOBCA1 | |
| SCHEMBL2804208 | 0.81 | PTGES (0.47) | PTGESPTGES2HDAC6MAOBCA1 | |
| SCHEMBL978913 | 0.81 | PTGES (0.47) | PTGESEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | claimed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PTGES 9/4885SRD5A1 147/4885PTGES2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.